Reimbursement News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Genzyme keeps separate HCPCS code: Genzyme's Synvisc hyaluronic acid-based product for treating osteoarthritic knee joints will continue to be paid at a higher rate than competing products in 2006, the firm announced Nov. 8. The decision maintains the 2005 rates and reverses CMS' proposal to place all viscosupplement products in the same J-code. Synvisc competes with Johnson & Johnson/Ortho Biotech'sOrthovisc, Sanofi-Aventis' Hyalgan and Smith & Nephew's Supartz (1"The Gray Sheet" June 20, 2005, p. 3). Orthovisc will continue to be paid using miscellaneous codes, according to the firm...
You may also be interested in...
Private Comparative Effectiveness Arbiter Is In Industry’s Interest – Attorney
Industry should develop a third-party comparative effectiveness review organization to preclude Congress from creating a similar body, Sidley Austin Brown & Wood partner Patrick Morrisey said Dec. 5
Private Comparative Effectiveness Arbiter Is In Industry’s Interest – Attorney
Industry should develop a third-party comparative effectiveness review organization to preclude Congress from creating a similar body, Sidley Austin Brown & Wood partner Patrick Morrisey said Dec. 5
Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees
Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc